Hypera and Bradsaúde see positive outlooks from financial analysts

Financial analysts are highlighting growth potential for two Brazilian companies, Hypera and Bradsaúde.

Hypera (HYPE3) is seeing renewed interest due to its GLP-1 medication, Semavy, used for diabetes and obesity. Institutions including Itaú BBA, XP Investimentos, and Bradesco BBI suggest the stock is undervalued. Projections indicate Semavy could generate approximately R$ 480 million in annual revenue by 2027, with quarterly revenues potentially reaching R$ 120 million.

Meanwhile, Bank of America (BofA) has initiated coverage on Bradsaúde (SAUD3) with a buy recommendation and a price target of R$ 19, suggesting a 26.5% upside. Despite a 31.2% increase in share value so far in 2026, analysts believe the current price does not fully reflect the company's diversified presence in health insurance, diagnostics, and hospitals, nor its controlled loss ratios.